Why the study?
Does KW-3902 inhibit adenosine-induced shortening of action potential duration in guinea pig atrial muscles?
Does KW-3902 inhibit adenosine-induced shortening of action potential duration in guinea pig atrial muscles?
KW-3902 inhibits adenosine-induced action potential duration shortening in guinea pig atria, supporting that this effect is mediated via adenosine A1-receptors.
Supports A1 mediation of adenosine APD effects in guinea pig atria; leaves open human translation.
We investigated the effects of KW-3902 (8-(noradamantan-3-yl)-1,3- dipropylxanthine), a newly-synthesized selective adenosine A1-receptor antagonist, on the shortening of action potential duration (APD) in guinea pig atria exposed to adenosine. The APD shortening by adenosine was inhibited by KW-3902 at higher than 10(-8) M, but not by 10(-5) M of KF17837, an adenosine A2-receptor antagonist. These results support the notion that the APD shortening by adenosine in atria is mediated via adenosine A1-receptors. The potency of KW-3902 in antagonizing the APD-shortening were similar to those in antagonizing the negative inotropic and chronotropic action of adenosine in the isolated right atria, suggesting that these responses to adenosine are mediated via the receptors of the same type.
No takes yet. Share an insight, caveat, or question.
Mori et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: